Critical role of IL-21 in modulating TH17 and regulatory T cells in Behçet disease

Géri, Guillaume; Terrier, B.; Rosenzwajg, Michèlle; Wechsler, B.; Touzot, Maxime; Seilhean, Danielle; Tran, Tú-Anh; Bodaghi, Bahram; Musset, Lucile; Soumelis, Vassili; Klatzmann, David; Cacoub, Patrice; Saadoun, David

doi:10.1016/j.jaci.2011.05.029

Cited by 200 publications

(138 citation statements)

References 25 publications

(24 reference statements)

Supporting

Mentioning

132

Contrasting

Unclassified

Order By: Relevance

“…This has recently been confirmed in a genome-wide association study (3). Recent data provide evidence for a critical role of interleukin-17, interleukin-21, and their modulating effect on Th17 and regulatory T cells (4). In line with this hypothesis is growing evidence for a central role of tumor necrosis factor ␣ (TNF␣) reflected by proposed treatment algorithms (5).…”

Section: Introductionmentioning

confidence: 77%

Behçet's disease: Successful treatment with infliximab in 7 patients with severe vascular manifestations. A retrospective analysis

Adler¹,

Baumgartner²,

Villiger³

2012

Arthritis Care & Research

View full text Add to dashboard Cite

Objective. To evaluate the therapeutic effect of infliximab in patients with inflammatory vascular lesions due to Behçet's disease (BD). Methods. Seven patients with clinical evidence of severe vascular BD were analyzed: 3 patients with aortic involvement, 1 with recurrent venous thrombosis of the pelvic veins, 1 with recurrent venous and arterial thromboses of the thigh, and 2 with retinal vasculitis. Infliximab was initiated with 3-5 mg/kg of body weight and infusions were repeated in intervals of 4 weeks as either first-line therapy in 3 patients or add on after failure of conventional immunosuppression in the remaining 4. Ongoing immunosuppression consists of a various combination of azathioprine (n ‫؍‬ 2), methotrexate (n ‫؍‬ 3), cyclosporine (n ‫؍‬ 3), and low-dose glucocorticoids (n ‫؍‬ 3). Results. Control of inflammation was seen 1-5 days after infliximab induction in all patients. C-reactive protein level was reduced from a mean of 89 mg/liter prior to infliximab to 9 mg/liter thereafter. Vision increased rapidly in patients with retinal vasculitis. Vascular grafts remained patent. The inflamed and dissected aortic wall healed over a period of 6 months. Infliximab could be stopped in 2 patients; intervals could be extended in 4 to a maximum of 8 weeks. Infliximab and basic immunosuppression were well tolerated; no drug-induced side effects were recorded. Conclusion. Infliximab is effective in inducing and maintaining remission of vasculitic activity in patients with BD. The rapid effect together with excellent tolerability suggests that infliximab should be considered as a first-line agent in severe vascular BD.

show abstract

Section: Introductionmentioning

confidence: 77%

Behçet's disease: Successful treatment with infliximab in 7 patients with severe vascular manifestations. A retrospective analysis

Adler¹,

Baumgartner²,

Villiger³

2012

Arthritis Care & Research

View full text Add to dashboard Cite

show abstract

“…[15] Biopsies taken from RAS patients have found the presence of T cells and polymorphonuclear leukocytes in lesions, leading to the consideration that these cells play a role in pathogenesis. [16] Additionally in Behçet''s disease, with similar etiopathogenesis to RAS, hypersensitivity of T lymphocytes to a variety of antigens was not identified, with increased platelet and neutrophil activity was shown in blood parameters. [17][18][19] Neutrophil to lymphocyte ratio has come to the agenda in recent years as an easy and practical method measured in blood that provides important information to determine diagnosis and prognosis of a variety of diseases.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of mean platelet volume and neutrophil to lymphocyte ratio as a diagnostic indicator in patients with recurrent aphthous stomatitis

Şereflican¹,

Şereflican²,

Tuman³

et al. 2016

ENT Updates

View full text Add to dashboard Cite

“…A Th1 predominant response has been observed in many studies on RAS, and some studies have demonstrated evidence of a Th2 response 10, 47, 60, 61. RAS may involve a mixture of Th1 and Th2 activity and increased activity of Th17 cells 63, 64, 65. In addition to cellular immune activation, evidence of humoral immune activation has been identified in patients with RAS, and autoantibodies against numerous targets have been described 47, 66, 67.…”

Section: Discussionmentioning

confidence: 99%

Recurrent aphthous stomatitis may be a precursor or risk factor for specific cancers: A case‐control frequency‐matched study

et al. 2018

View full text Add to dashboard Cite

BackgroundRecurrent aphthous stomatitis (RAS) is considered a prophase symptom in patients with specific cancers. This study assessed the association between RAS and subsequent onset of cancer based on a nationwide population‐based database in Taiwan.Materials and MethodsWe selected study participants from the National Health Insurance Research Database from January 2000 to December 2008. Patients in the non‐RAS cohort were matched to case study patients at a 1:1 ratio through frequency matching. All participants were followed up for at least 5 years, and those who received cancer diagnoses during follow‐up were identified.ResultsAmong 52 307 patients with and 52 304 patients without RAS, the combined hazard ratio (HR) of all subsequent cancer cases was 1.3 (95% confidence interval [CI]: 1.25‐1.35, P = 0). RAS diagnosis was associated with risk for cancers of the head and neck (aHR = 2, 95% CI: 1.8‐2.3), colon (aHR = 1.2, 95% CI: 1.1‐1.4), liver (aHR = 1.1, 95% CI: 1‐1.3), pancreas (aHR = 1.4, 95% CI: 1.1‐1.7), skin (aHR = 1.4, 95% CI: 1.2‐1.7), breast (aHR = 1.2, 95% CI: 1.1‐1.4), and prostate (aHR = 1.5, 95% CI: 1.3‐1.8), as well as hematologic cancers (aHR = 1.6, 95% CI: 1.3‐1.9). A higher risk was observed for male patients (aHR = 1.35, 95% CI: 1.28‐1.42) than for female patients (aHR = 1.25, 95% CI: 1.18‐1.31) with RAS.Conclusions RAS was associated with specific cancers. Susceptible RAS patients should be screened for specific cancers.

show abstract

Critical role of IL-21 in modulating TH17 and regulatory T cells in Behçet disease

Cited by 200 publications

References 25 publications

Behçet's disease: Successful treatment with infliximab in 7 patients with severe vascular manifestations. A retrospective analysis

Behçet's disease: Successful treatment with infliximab in 7 patients with severe vascular manifestations. A retrospective analysis

Evaluation of mean platelet volume and neutrophil to lymphocyte ratio as a diagnostic indicator in patients with recurrent aphthous stomatitis

Recurrent aphthous stomatitis may be a precursor or risk factor for specific cancers: A case‐control frequency‐matched study

Contact Info

Product

Resources

About